Direct accesses
Go to main menu
Go to main content
Menu
Search the site
Contact
Careers
You are viewing the website in English
en
fr
Search the site
Who
we are
Company
Leadership
Collaborations
Diseases
we target
Diseases we target
Leber Hereditary Optic Neuropathy (LHON)
Retinitis Pigmentosa (RP)
Geographic Atrophy in Dry-AMD
Our
technologies
Technologies we are applying
Gene Therapy
Mitochondrial Targeting Sequence (MTS)
Optogenetics
Clinical development Summary
Investors
Company Overview
Financial press releases
Investor Newsletters
Events & presentations
Stock information & Financial agenda
Governance
Documentation
Media
General Meeting
Year
All
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
News type
All
Regulatory
Clinical
Conferences
Corporate
Finance
General Meeting
Product candidates
Science & Technology
Other
Subject
All
General Assembly
Company and personnel
GS010 - LUMEVOQ
GS030
Technologies
Other
30 May 2024
Gensight Biologics announces the approval of all resolutions supported by the Board of Directors at its Combined General Meeting
07 May 2024
Annual General Meeting on May 29, 2024
31 May 2023
Annual General Meeting on June 21, 2023
10 May 2023
GenSight Biologics Announces the Filing of its 2022 Universal Registration Document and Reschedules its Annual General Meeting on June 21, 2023
04 May 2022
Annual General Meeting on May 25, 2022 Procedures for obtaining preparatory documents for the General Meeting
29 Apr 2021
Annual General Meeting 2021
08 April 2021
Annual General Meeting on April 29, 2021
22 April 2020
GenSight Biologics will hold its General Meeting on April 29, 2020 behind closed doors
07 Jan 2019 - 10 Jan 2019
37th Annual J.P. Morgan Healthcare Conference, San Francisco (CA), USA
Go back to the page of the page